Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate.
M Anafi, A Gazit, A Zehavi, Y Ben-Neriah, A Levitzki
Index: Blood 82(12) , 3524-9, (1993)
Full Text: HTML
Abstract
We report on the potency of two Tyrphostin tyrosine kinase blockers, AG 1112 and AG 568, to inhibit p210bcr-abl tyrosine kinase activity in K562 cells, concomitant with the induction of erythroid differentiation. AG 568 and especially AG 1112 represent a specific group of nontoxic protein tyrosine kinase blockers among more than 1,400 tested. These compounds possess therapeutic potential for purging Philadelphia chromosome-positive cells in preparation for autologous bone marrow transplantation in chronic myelogenous leukemia.
Related Compounds
Related Articles:
Protein kinase inhibitors as a therapeutic modality.
2003-06-01
[Acc. Chem. Res. 36(6) , 462-9, (2003)]